Welcome to our dedicated page for Bionexus Gene La SEC filings (Ticker: BGLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNexus Gene Lab Corp (BGLC) SEC filings page on Stock Titan provides direct access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. BioNexus is a Wyoming-incorporated biotechnology and specialty materials group listed on The Nasdaq Stock Market LLC, and its filings offer detailed insight into strategic agreements, capital markets activity, governance, and financial reporting.
Among the most informative documents are the company’s current reports on Form 8-K. Recent 8-K filings describe material definitive agreements such as the Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics and Tongshu Biotechnology, which outlines BioNexus’s planned 15% equity stake in Fidelion and cross-equity alignment around the VitaGuard™ MRD platform. Other 8-Ks cover the Equity Distribution Agreement with Maxim Group LLC for a $20 million at-the-market program, the non-binding term sheet with BirchBioMed Inc., and key governance changes including the appointment of a new Chief Financial Officer.
Investors can also review shelf registration statements and related disclosures referenced in 8-K exhibits, which explain how BioNexus structures its access to capital for diagnostics, CDMO, and therapeutic initiatives. Notifications such as the Form 12b-25 (NT 10-Q) provide context when a quarterly report is filed later than the original due date, including reasons such as transitions in financial leadership.
On Stock Titan, these filings are complemented by AI-powered summaries designed to clarify the practical meaning of complex documents. Users can quickly understand the implications of new equity facilities, cross-shareholding arrangements, licensing agreements, and governance updates without reading every page. Real-time updates from EDGAR ensure that newly filed 8-Ks, 10-Ks, 10-Qs, and other forms appear promptly, while insider transaction reports on Form 4 and proxy-related materials, when filed, can be used to track ownership changes and board-level decisions.
Together, the BioNexus SEC filings and AI-generated insights help readers analyze how the company structures its partnerships, manages its Nasdaq listing, and supports its strategy in precision diagnostics, CDMO services, and specialty materials.
BioNexus Gene Lab Corp. entered into an Equity Distribution Agreement with Maxim Group LLC to establish an at-the-market program under which the Company may offer and sell up to $20,000,000 of common stock, from time to time, through the agent.
Sales, if any, may be made on The Nasdaq Capital Market or otherwise at prevailing, related, or negotiated prices. The Company is not obligated to sell shares, and the agent is not required to purchase shares. No sales will occur unless the Company’s shelf Registration Statement on Form S-3 (File No. 333-291379) is declared effective and an applicable prospectus supplement is filed.
The agreement includes customary representations, covenants, indemnification, and termination rights. The Company also announced the ATM program via a press release furnished as an exhibit.
BioNexus Gene Lab Corp. (BGLC) entered a definitive share subscription and shareholders’ agreement with Fidelion Diagnostics to form a strategic alliance around the VitaGuard MRD platform. Upon completion, BGLC will subscribe for new Fidelion shares to hold at least 15.0% of Fidelion’s enlarged capital, and will issue restricted shares representing 19.9% of BGLC’s outstanding common stock (pre-issuance) to Fidelion as consideration.
Closing is subject to specified conditions precedent, including an exclusive Southeast Asia IP license between BGLC and Fidelion and customary consents. Governance terms allow BGLC to appoint two directors to Fidelion’s board (one Singapore resident), with reserved matters requiring enhanced approvals. Transfer restrictions, pre-emptive and over‑subscription rights, and SIAC arbitration are included.
Related‑person disclosure: as of November 11, 2025, BGLC’s CEO Su‑Leng Tan Lee beneficially owns approximately 4.1% of Fidelion and is expected to serve as Fidelion’s initial CEO; independent and disinterested directors approved the transactions, and he abstained. The BGLC share issuance will be conducted offshore under Regulation S.
BioNexus Gene Lab Corp. filed a shelf registration to offer up to $100,000,000 of securities (common stock, preferred stock, warrants, rights and units) from time to time, with terms to be set in future supplements. The filing also includes a sales agreement prospectus for an at‑the‑market program to sell up to $3,557,000 of common stock through Maxim Group LLC as exclusive sales agent.
Under the ATM, shares may be sold at prevailing market prices, and BioNexus will pay Maxim a 2.5% commission on gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes. As of this prospectus, the aggregate market value of common stock held by non‑affiliates was $10,779,582, based on 1,796,597 shares and a $6.00 per‑share price used for SEC eligibility. Pursuant to General Instruction I.B.6, while public float is under $75 million, sales off the shelf are limited to no more than one‑third of public float in any 12‑month period.
BioNexus’s common stock trades on Nasdaq as BGLC. The company is an emerging growth and smaller reporting company and may use scaled disclosures.
BioNexus Gene Lab Corp. (BGLC) furnished a press release under Regulation FD announcing a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. The proposed collaboration contemplates BGLC leading Birch’s current financing round via a strategic equity investment and jointly commercializing Birch’s FS2 (kynurenic acid) topical platform in Southeast Asia.
The Term Sheet is described as a framework for continued discussions, and the company notes there is no assurance a definitive agreement will be executed or that the contemplated transactions will be completed.
BioNexus Gene Lab Corp (BGLC) 10-Q excerpts show corporate and balance-sheet details without full financial statements. The company reports 300,000,000 shares authorized with 1,796,597 shares outstanding in one period and 1,796,766 shares outstanding at December 31, 2024 (post-reverse split basis). The company disclosed the 2017 acquisition of Bionexus Gene Lab Sdn. Bhd., later renamed MRNA Scientific Sdn. Bhd. It records trade receivables at invoiced amounts less an allowance for expected credit losses, writes off uncollectible accounts, and notes typical receivable terms range from 30 to 90 days. One customer was charged interest at 6% per annum through June 2023 and the rate increased to 8.4% from July 2023. The filing notes 1,044,351 shares issued due to a round-up and corporate governance actions at subsidiary Chemrex Corporation Sdn. Bhd., including additional directors, policy updates, and enhanced reporting to the company CFO and Audit Committee.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) filed an 8-K to disclose a Regulation FD communication. On 30 July 2025 the company signed a non-binding term sheet with Singapore-based Fidelion Diagnostics Pte Ltd. The parties are negotiating a cross-equity strategic alliance and have granted BGLC exclusive commercialization rights in Southeast Asia to Fidelion’s VitaGuard™ minimal-residual-disease (MRD) testing platform, a precision-oncology technology aimed at detecting trace cancer cells post-treatment.
The agreement is still preliminary; no financial terms, timelines or definitive contracts were announced. The company framed the deal as a potential “DeepSeek Moment” for oncology diagnostics in the region. No guidance, revenue impact or financing details accompanied the disclosure, and the item is being furnished, not filed, so it carries no immediate accounting effect.
FAQ
What is the current stock price of Bionexus Gene La (BGLC)?
What is the market cap of Bionexus Gene La (BGLC)?
